|
1）Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012; 82: 737-47
|
|
|
|
2）Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009; 20: 381-7
|
|
|
|
|
|
3）Linefsky JP, O’Brien KD, Katz R, et al. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study. J Am Coll Cardiol. 2011; 58: 291-7
|
|
|
|
|
|
4）Scialla JJ, Lau WL, Reilly MP, et al; Chronic Renal Insufficiency Cohort Study Investigators. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 2013; 83: 1159-68
|
|
|
|
|
|
5）Bellasi A, Mandreoli M, Baldrati L, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol. 2011; 6: 883-91
|
|
|
|
|
|
6）Schwarz S, Trivedi BK, Kalantar-Zadeh K, et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006; 1: 825-31
|
|
|
|
|
|
7）Zoccali C, Ruggenenti P, Perna A, et al; REIN Study Group. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011; 22: 1923-30
|
|
|
|
|
|
8）De Nicola L, Chiodini P, Zoccali C, et al; SIN-TABLE CKD Study Group. Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol. 2011; 6: 2421-8
|
|
|
|
|
|
9）Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Outcomes associated with serum phosphorus leve in males with non-dialysis dependent chronic kidney disease. Clin Nephrol. 2010; 73: 268-75
|
|
|
|
|
|
10）Voormolen N, Noordzij M, Grootendorst DC, et al; PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007; 22: 2909-16
|
|
|
|
|
|
11）Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16: 520-8
|
|
|
|
|
|
12）Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5: 2251-7
|
|
|
|
|
|
13）Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res. 2006; 98: 905-12
|
|
|
|
|
|
14）Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121: 4393-408
|
|
|
|
|
|
15）Hamano T, Matsui I, Mikami S, et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol. 2010; 21: 1998-2007
|
|
|
|
|
|
16）Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007; 72: 1255-61
|
|
|
|
|
|
17）Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012; 7: 487-93
|
|
|
|
|
|
18）Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013; 83: 959-66
|
|
|
|
|
|
19）Isakova T, Barchi-Chung A, Enfield G, et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol. 2013; 8: 1009-18
|
|
|
|
|
|
20）Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant. 2011; 26: 2567-71
|
|
|
|
|
|
21）Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014; 9: 543-52
|
|
|
|
|
|
22）Sigrist M, Tang M, Beaulieu M, et al. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Nephrol Dial Transplant. 2013; 28: 161-9
|
|
|
|
|
|
23）Spatz C, Roe K, Lehman E, et al. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease. Nephron Clin Pract. 2013; 123: 61-6
|
|
|
|
|
|
24）Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol. 2013; 24: 842-52
|
|
|
|
|
|
25）Jimbo R, Kawakami-Mori F, Mu S, et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int. 2014; 85: 1103-11
|
|
|
|
|
|
26）Seiler S, Rogacev KS, Roth HJ, et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol. 2014; 9: 1049-58
|
|
|
|
|
|
27）Isakova T, Xie H, Yang W, et al; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305: 2432-9
|
|
|
|
|
|
28）Kendrick J, Cheung AK, Kaufman JS, et al; HOST Investigators. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011; 22: 1913-22
|
|
|
|
|
|
29）van Venrooij NA, Pereira RC, Tintut Y, et al. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant. 2014; 29: 1525-32
|
|
|
|
|
|
30）Kuro-o M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol. 2013; 9: 650-60
|
|
|
|
|
|
31）Ewence AE, Bootman M, Roderick HL, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008; 103: e28-34
|
|
|
|
|
|
32）Sage AP, Lu J, Tintut Y, et al. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. 2011; 79: 414-22
|
|
|
|
|
|
33）Smith ER, Ford ML, Tomlinson LA, et al. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant. 2012; 27: 1957-66
|
|
|
|
|
|
34）Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012; 23: 1407-15
|
|
|
|
|